Literature DB >> 2576974

Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates.

G Vasanthakumar1, N K Ahmed.   

Abstract

Human K562 erythroleukemia cells were selected in sequential steps for resistance to daunorubicin (K562/III) and found to be cross-resistant to a number of drugs, including vincristine, dactinomycin, doxorubicin, etoposide, and teniposide. In this paper, we report that the K562/III subline showed amplification of an mdr1 gene and its 4.5 kb transcript. Our results also show that non-ionic oligonucleoside methylphosphonates, complementary to the initiation codon and 15 bases upstream of the mdr1 gene, can completely inhibit the synthesis of P-glycoprotein and partially increase the toxicity of daunorubicin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2576974

Source DB:  PubMed          Journal:  Cancer Commun        ISSN: 0955-3541


  5 in total

1.  Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism.

Authors:  C Boiziau; R Kurfurst; C Cazenave; V Roig; N T Thuong; J J Toulmé
Journal:  Nucleic Acids Res       Date:  1991-03-11       Impact factor: 16.971

2.  Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes).

Authors:  S Akhtar; S Basu; E Wickstrom; R L Juliano
Journal:  Nucleic Acids Res       Date:  1991-10-25       Impact factor: 16.971

Review 3.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

4.  Deprotection of methylphosphonate oligonucleotides using a novel one-pot procedure.

Authors:  R I Hogrefe; M M Vaghefi; M A Reynolds; K M Young; L J Arnold
Journal:  Nucleic Acids Res       Date:  1993-05-11       Impact factor: 16.971

5.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.